- Home
- GOODO vs VCEL Comparison
GOODO vs VCEL Comparison
Compare GOODO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GOODO
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Current Price
Company Overview
Basic Information| Metric | GOODO | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | GOODO | VCEL |
|---|---|---|
| Price | $19.83 | $32.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.50 |
| AVG Volume (30 Days) | 6.8K | ★ 527.5K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | N/A | $17.95 |
| P/E Ratio | ★ N/A | $98.34 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $18.30 | $29.24 |
| 52 Week High | $22.20 | $48.75 |
Technical Indicators
Market Signals| Indicator | GOODO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 40.44 |
| Support Level | $19.52 | $31.24 |
| Resistance Level | $20.27 | $38.48 |
| Average True Range (ATR) | 0.22 | 1.34 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 32.66 | 31.94 |
Price Performance
Historical ComparisonAbout GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.